VXRT
Vaxart, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.48
+6.85%Year over year
Reported trailing growth
- Revenue
- +201.1%
- EBITDA
- +206.8%
- EBIT
- +171.4%
- EPS
- +168.2%
- Free cash flow
- +189.8%
- Operating cash flow
- +191.6%
Forward estimates
Based on analyst estimates
- Revenue
- -89.7%
- EBITDA
- —
- EPS
- +266.7%
Three-year CAGR
- Revenue
- +1204.0%
- EBITDA
- +151.4%
- EBIT
- +127.3%
- Net income
- +124.4%
- EPS
- +150.0%
- Free cash flow
- +116.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026